OPR - Delayed Quote USD

LXRX Jul 2024 5.000 put (LXRX240719P00005000)

2.9500

0.0000

(0.00%)

As of March 27 at 3:15 PM EDT. Market Open.

Key Events

Loading Chart for LXRX240719P00005000

9/21 12:03 PM

DELL

Previous Close 2.9500
Open 2.9500
Bid 3.2000
Ask 3.8000
Strike 5.00
Expire Date 2024-07-19
Day's Range 2.9500 - 2.9500
Contract Range --
Volume 5
Open Interest 9

Lexicon Pharmaceuticals to Host 2024 Investor Day

Lexicon Pharmaceuticals to Host 2024 Investor Day

All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy

All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

15 Hot Penny Stocks On the Move

15 Hot Penny Stocks On the Move